BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Theravance Biopharma (TBPH)Theravance BiopharmaEarnings

Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 Strategic Review Committee accelerating evaluation of opportunities to maximize

Related news

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2025-11-10 21:05 EST

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

LUNGPulmonx2026-03-04 21:06 EST

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

LUNGPulmonx2026-02-20 13:00 EST

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

XAIRBeyond Air2026-02-13 12:30 EST

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

PULMPulmatrix2026-02-26 13:05 EST

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

SVRASavara, Inc.2018-11-07 21:02 EST

Savara Reports Third Quarter 2018 Financial Results and Provides Business Update

RVPHReviva Pharmaceuticals2026-03-30 10:05 EST

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Stock data

Close
16.92 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States